25 March 2021, Bergen - Today, Lifecare announces that The European Patent
Office has issued its intent to grant Lifecare a new patent, expanding
Lifecare's patent protection in time and scope. Lifecare has reviewed the
examining division's comments to the patent application and concludes that the
suggested cosmetic changes are acceptable. On this base, Lifecare expects the
European Patent Office to grant the patent within the next few months. 

The new patent will ensure protection until 2038. It will be a fundamental
addition to Lifecare's IP and an important next step from Lifecare's research
and development to commercialization. 

The patent is for an updated sensor measuring system comprised of the well-known
and already proprietary osmotic pressure based Sencell core technology for
glucose, and an additional reference sensor to measure environmentally induced
general pressure changes. The patent is for Lifecare's application of
"interstitial fluid osmotic pressure measuring device system and method." 

"This European patent will strengthen our position for correct and continuous
monitoring of blood sugar, in people with diabetes, through the development of a
miniature sensor. The patent covers Lifecare's Sencell technology in the sensor,
which is the size of a grain of rice, that will be used in the recently approved
human pilot studies," says Joacim Holter, CEO Lifecare. "Existing continuous
glucose measurement technologies are inconvenient, complicated, costly, and have
limited lifetime. The sensor design described in our new patent intends to
improve signal amplitude, increase the accuracy of subcutaneous glucose
assessment, and to improve sensor longevity and robustness against environmental
changes." 

Patent broadens the scope and application of the Sencell technology
The patent opens up the opportunities to expand the use of the Sencell
technology. It will increase the scope of protection to include measurement of
many parameters in the interstitial fluid, including but not limited to lactate,
fructose, and calcium, in addition to glucose. 

"This new patent substantially strengthens the protection of Lifecare's core
Sencell technology," says Prof. Andreas Pfützner, Lifecare's Chief Scientific
Officer and one of the inventors of the new patent. "The patent covers an
essential part of the sensor design, which will be important when we start to
use Sencell for additional analysis, beyond glucose, in the future."

About Lifecare
Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature
sensor for correct and continuous monitoring of blood sugar in people with
diabetes. Its patented technology is also used as a central component in a rapid
test for Covid-19 and as a measurement unit for reading out different
biomarkers.

For more information, please contact: 
Joacim Holter, CEO
Phone: +47 40 05 90 40
Email: joacim.holter@lifecare.no